Biotech companies face the challenge of cutting costs to make their resources last through the economic downturn, while continuing to seek international patent protection for their inventions to ensure long-term viability.
Because French academic science has only recently become entrepreneurial, the challenge for technology transfer has been to market biotechnologies strongly to potential licensees and corporate sponsors.
